This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (38)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jean M. B. Moure, MD; John P. Whitecar, Jr., MD; Gerald P. Bodey, MD

Arch Neurol. 1970;23(4):365-368.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ASPARAGINASE is a new antitumor agent which was reported by Tallal et al¹ in 1969, to be effective in inducing remission in patients with acute leukemia. This agent is an enzyme which catalyzes the hydrolysis of asparaginase to L-aspartic acid and ammonia. Clinical trials have been conducted with a preparation derived from Escherichia coli.

The early experience of Hill et al² in 1967 with asparaginase suggested that this agent inhibited only tumor cells and had no effect on normal host cells. However, more extensive clinical trials by Whitecar et al,³ have shown that there was a decrease in several plasma proteins such as fibrinogen, albumin, insulin, and amylase, indicating that asparaginase inhibited protein synthesis by normal cells.

During a clinical trial of asparaginase in patients with leukemia and metastatic cancer at the University of Texas, MD Anderson Hospital at Houston, several patients developed lethargy, confusion, . . . [Full Text PDF of this Article]

Author Affiliations
Houston

From the University of Texas, MD Anderson Hospital and Tumor Institute, Houston.

Footnotes
Accepted for publication May 29, 1970.

Reprint requests to Laboratory of Electroencephalography, MD Anderson Hospital, Houston 77025 (Dr. Moure).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?